← Leaderboards
Beth A Weaver
University Of Wisconsin-Madison
$5,539,731
Attributed
$7,430,008
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,430,008 · 5
By mechanism
R01$7,430,008 · 5
Top collaborators
- Mark E Burkard7 shared
Most similar at University Of Wisconsin-Madison
Same institution · by research overlap
- Mark E Burkard$10,864,762
- Amy Trentham-Dietz$16,896,140
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMitosisMitoticMalignant NeoplasmsTumorAffectChromosomesCell DeathClinically RelevantLaboratoriesMammary NeoplasmsMalignant Breast NeoplasmChromosomal InstabilityTumor SuppressionClinical TrialsGenesPreventDefectMouse ModelPatient-Focused OutcomesInterphaseCancer PatientCell DivisionBreast Cancer Model
Grant awards (17)
Mechanisms of paclitaxel sensitivity and resistance$559,860
R01 · FY2025 · CA · contact PI
Non-canonical roles of Mitotic Arrest Deficient 1 (Mad1) in tumor promotion$469,883
R01 · FY2025 · CA · contact PI
Mechanisms of paclitaxel sensitivity and resistance$529,300
R01 · FY2024 · CA · contact PI
Non-canonical roles of Mitotic Arrest Deficient 1 (Mad1) in tumor promotion$446,389
R01 · FY2024 · CA · contact PI
Mechanisms of Plk1 at the mitotic centromere$305,672
R01 · FY2024 · GM · contact PI
Impact of chromosomal instability on sensitivity to microtubule-targeting drugs in breast cancer$533,016
R01 · FY2023 · CA · contact PI
Non-canonical roles of Mitotic Arrest Deficient 1 (Mad1) in tumor promotion$460,485
R01 · FY2023 · CA · contact PI
Impact of chromosomal instability on sensitivity to microtubule-targeting drugs in breast cancer$533,016
R01 · FY2022 · CA · contact PI
Non-canonical roles of Mitotic Arrest Deficient 1 (Mad1) in tumor promotion$469,883
R01 · FY2022 · CA · contact PI
Impact of chromosomal instability on sensitivity to microtubule-targeting drugs in breast cancer$542,912
R01 · FY2021 · CA · contact PI
Impact of chromosomal instability on sensitivity to microtubule-targeting drugs in breast cancer$542,209
R01 · FY2020 · CA · contact PI
Impact of chromosomal instability on sensitivity to microtubule-targeting drugs in breast cancer$540,241
R01 · FY2019 · CA · contact PI
Mitosis, Aneuploidy and Cancer$304,917
R01 · FY2015 · CA · contact PI
Mitosis, Aneuploidy and Cancer$295,769
R01 · FY2014 · CA · contact PI
Mitosis, Aneuploidy and Cancer$286,622
R01 · FY2013 · CA · contact PI
Mitosis, Aneuploidy and Cancer$304,917
R01 · FY2012 · CA · contact PI
Mitosis, Aneuploidy and Cancer$304,917
R01 · FY2011 · CA · contact PI